AstraZeneca (LON:AZN) PT Raised to £130

AstraZeneca (LON:AZN) had its target price boosted by Berenberg Bank from £120 ($150.75) to £130 ($163.32) in a research note released on Friday morning, MarketBeat reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a report on Monday, February 12th. Deutsche Bank Aktiengesellschaft restated a hold rating and set a £105 ($131.91) price target on shares of AstraZeneca in a report on Tuesday, April 23rd. Jefferies Financial Group restated a hold rating and set a £110 ($138.19) price target on shares of AstraZeneca in a report on Friday, February 16th. UBS Group cut their price target on shares of AstraZeneca from £107 ($134.42) to GBX 9,900 ($124.37) and set a sell rating for the company in a report on Monday, February 12th. Finally, JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a report on Thursday, April 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of Moderate Buy and an average target price of £117.57 ($147.70).

AstraZeneca Price Performance

Shares of AZN traded up GBX 68 ($0.85) during mid-day trading on Friday, hitting £121.18 ($152.24). 2,186,125 shares of the company were exchanged, compared to its average volume of 2,210,976. The stock has a market cap of £187.83 billion, a price-to-earnings ratio of 3,746.75, a price-to-earnings-growth ratio of 0.93 and a beta of 0.19. The company has a debt-to-equity ratio of 92.51, a quick ratio of 0.59 and a current ratio of 0.89. AstraZeneca has a 1-year low of GBX 9,461 ($118.86) and a 1-year high of £124.88 ($156.88). The company has a 50 day moving average of £108.03 and a 200-day moving average of £104.95.

AstraZeneca Increases Dividend

The business also recently declared a dividend, which was paid on Monday, March 25th. Investors of record on Thursday, February 22nd were paid a dividend of GBX 156 ($1.96) per share. This is a positive change from AstraZeneca’s previous dividend of $71.80. This represents a yield of 1.49%. The ex-dividend date was Thursday, February 22nd. AstraZeneca’s dividend payout ratio (DPR) is currently 7,058.82%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.